The ASSURE Study: HIV-1 Suppression Is Maintained with Bone and Renal Biomarker Improvement 48 Weeks after Ritonavir Discontinuation and Randomized Switch to Abacavir/Lamivudine + Atazanavir. HIV Medicine, 17(2): 106-117.

In by AHF

File Type: pdf
Categories: 2016
Tags: 2015-2019
Author: Bhatti L, DeJesus E, Edelstein H, Margolis DA, Ross LL, Shaefer MS, Small CB, Weinberg WG, Wohl DA, Zhao HH